Authors:Nóra Gyöngyösi, Kende Lőrincz, Sarolta Kárpáti and Norbert Wikonkál
Atteno, M., Peluso, R., Costa, L., et al.: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin
Authors:Péter Bacsur, Soma Skribanek, Ágnes Milassin, Klaudia Farkas, Renáta Bor, Anna Fábián, Mariann Rutka, Anita Bálint, Kata Judit Szántó, Tibor Tóth, Ferenc Nagy, Zoltán Szepes, Krisztina Boda and Tamás Molnár
Bálint A, Rutka M, Végh Z, et al. Frequency and characteristics of
infusion reactions during biosimilar infliximab treatment in inflammatory bowel
diseases: results from Central European nationwide cohort. Expert
Authors:Meaghan M. Sebeika, Nicholas G. Gedeon, Sara Sadler, Nicholas L. Kern, Devan J. Wilkins, David E. Bell and Graham B. Jones
Interest in the field of antibody—drug conjugates (ADCs) has grown exponentially over the past decade. As the product pipeline grows, there is increasing need for robust chemistries which allow selective and efficient functionalization of the antibody cores for introduction of appropriate linkers and spacer groups. Under conventional bioconjugation conditions, product heterogeneity often results, and the drug-to-antibody ratios (DAR) are inconsistent. Based on our experience in protein derivatization, we have investigated the potential for continuous-flow microreactor technology to expedite and facilitate such processes. We demonstrate its potential using reagent proteins and the chimeric monoclonal antibody infliximab (Remicade™).